Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Equity Average (2016 - 2025)

Historic Equity Average for Sunshine Biopharma (SBFM) over the last 13 years, with Q3 2025 value amounting to $24.9 million.

  • Sunshine Biopharma's Equity Average rose 279.21% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 279.21%. This contributed to the annual value of $22.4 million for FY2024, which is 437.3% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Equity Average of $24.9 million as of Q3 2025, which was up 279.21% from $24.2 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Equity Average peaked at $41.1 million during Q3 2022, and registered a low of -$1.0 million during Q3 2021.
  • Moreover, its 5-year median value for Equity Average was $23.0 million (2024), whereas its average is $18.8 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 654431.45% in 2022, then crashed by 4521.33% in 2023.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Equity Average stood at -$481135.0 in 2021, then surged by 6544.31% to $31.0 million in 2022, then tumbled by 30.38% to $21.6 million in 2023, then grew by 12.44% to $24.3 million in 2024, then grew by 2.77% to $24.9 million in 2025.
  • Its last three reported values are $24.9 million in Q3 2025, $24.2 million for Q2 2025, and $23.1 million during Q1 2025.